GlassScriptPhysician profile
Jon Anton Sangeorzan
NPI 1306820378
$998.03
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $107 · 2022: $94.80 · 2023: $96.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $96.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $96.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $246.42 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $233.49 | 2019-2023 | Recarbrio, Dificid, Zerbaxa |
| Viiv Healthcare Company | $185.45 | 2019-2022 | |
| Abbvie INC. | $83.19 | 2019-2023 | Teflaro, Dalvance, Avycaz |
| Melinta Therapeutics, LLC | $53.76 | 2019-2022 | |
| Allergan, INC. | $40.86 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $37.90 | 2019 | |
| Nabriva Therapeutics, Plc | $23.80 | 2020 | |
| Smith+Nephew, INC. | $21.98 | 2019 | |
| Medline Industries LP | $20.97 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $13.97 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.06 | 2019 | |
| Dynavax Technologies Corporation | $12.23 | 2019 | |
| Insmed, INC. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Sangeorzan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.